Department of the General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
Department of Dermatology, The Second Hospital of Jilin University, Changchun, Jilin Province, China.
World J Surg Oncol. 2020 Feb 3;18(1):26. doi: 10.1186/s12957-020-1799-x.
Even with the augmentative application of anal-preservation surgery in low rectal cancer, the role and indications of laparoscopic intersphincteric resection (Lap ISR) are still under debate, especially for T3 or node-positive (T3N0M0, T1-3N+M0) cancer, mainly due to the oncological safety and functional outcomes. INTRABEAM (Carl Zeiss, Germany) intraoperative radiotherapy (IORT) using low-energy X-rays features in accurate irradiation, less exposure, and reduced complications. Taking advantages of Lap ISR and INTRABEAM IORT, this innovative approach aims to increase the probability of the anal preservation with acceptable postoperative outcomes.
From December 2015 to August 2019, we retrospectively analyzed the short-term outcomes of 12 patients evaluated preoperatively with T3 or node-positive (T3N0M0, T1-3N+M0) primary locally advanced low rectal cancer. They all had received Lap ISR and INTRABEAM IORT with a dose of 16-18 Gy applied by an applicator through the anus (natural orifice). Then, with no pre- or postoperative radiotherapy given, the patients were suggested to receive 6-8 cycles of the XELOX chemotherapy regimen (oxaliplatin, 130 mg/m and capecitabine, 1000 mg/m).
All patients achieved R0 resection. The median radiation time was 27 min and 15 s, and the mean radiative dose was 17.3 Gy (range 16-18 Gy). The median follow-up time was 18.5 months (range 3-45 months). Two patients experienced local recurrence. Two male patients experienced anastomotic stenosis. Furthermore, one of them experienced perianal abscess and the other one experienced pulmonary metastasis after refusing to receive chemotherapy. One female patient with internal anal sphincter invasion experienced distant metastases to the liver and gluteus maximus muscle 35 months after IORT. No acute radiation injuries or symptoms were observed. Although they experienced a reduction in anal function, every patient was satisfied with the postoperative outcomes.
For patients evaluated preoperatively with T3 or node-positive (T3N0M0, T1-3N+M0) primary locally advanced low rectal cancer, Lap ISR with INTRABEAM IORT may be a safe and feasible approach for anal preservation without compromising oncological outcomes.
即使在低位直肠癌中采用保肛手术,腹腔镜经肛门内括约肌切除术(Lap ISR)的作用和适应证仍存在争议,尤其是对于 T3 或淋巴结阳性(T3N0M0、T1-3N+M0)的癌症,主要是因为其在肿瘤学安全性和功能结果方面存在争议。INTRABEAM(德国卡尔蔡司公司)使用低能量 X 射线的术中放疗(IORT)具有精确照射、低暴露和减少并发症的优点。利用 Lap ISR 和 INTRABEAM IORT 的优势,这种创新方法旨在提高保肛概率,同时获得可接受的术后结果。
自 2015 年 12 月至 2019 年 8 月,我们回顾性分析了 12 例术前评估为 T3 或淋巴结阳性(T3N0M0、T1-3N+M0)原发性局部晚期低位直肠癌患者的短期结果。所有患者均接受了 Lap ISR 和 INTRABEAM IORT 治疗,应用肛门内(自然或经肛门)的施源器给予 16-18Gy 的剂量。然后,在没有术前或术后放疗的情况下,建议患者接受 6-8 个周期的 XELOX 化疗方案(奥沙利铂,130mg/m2 和卡培他滨,1000mg/m2)。
所有患者均达到 R0 切除。中位放疗时间为 27 分钟 15 秒,平均放疗剂量为 17.3Gy(范围 16-18Gy)。中位随访时间为 18.5 个月(范围 3-45 个月)。2 例患者出现局部复发。2 例男性患者出现吻合口狭窄。此外,其中 1 例患者拒绝接受化疗后出现肛周脓肿,另 1 例患者出现肺转移。1 例有内肛门括约肌侵犯的女性患者在接受 IORT 后 35 个月出现肝和臀大肌远处转移。未观察到急性放射损伤或症状。尽管患者的肛门功能有所下降,但每位患者均对术后结果感到满意。
对于术前评估为 T3 或淋巴结阳性(T3N0M0、T1-3N+M0)原发性局部晚期低位直肠癌的患者,Lap ISR 联合 INTRABEAM IORT 可能是一种安全可行的保肛方法,不会影响肿瘤学结果。